ClinicalTrials.gg
Not yet recruitingNCT07277296Updated Dec 11, 2025

CGUARDIANS III IDE Pivotal Trial

An interventional study of SwitchGuardTM NPS in Carotid Artery Stenosis, sponsored by InspireMD. Not yet recruiting. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by InspireMD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years to 82 Years
Sex
All
01

Study summary

This is a prospective, multi-center, single-arm, pivotal study. The objective of this study is to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection during Transcarotid Artery Revascularization procedures using the CGuard Prime Carotid Stent System 80 in the treatment of carotid artery stenosis in patients at high risk for complications from CEA.

Read the detailed description

This study is a prospective, multi-center, single arm pivotal study. The study shall not be blinded prior to, during or following the procedure. Patients undergoing transcarotid artery revascularization will be screened against the study inclusion/exclusion criteria. If the patient meets study eligibility requirements, they shall be invited to participate, provided informed consent and shall subsequently be assigned a study ID number.

Enrollment will be 103 pivotal patients. A maximum of 20% of patients will be enrolled at any single site. The total enrollment accounts for an estimate that up to 2 patients will exit the study prior to the 30-day primary endpoint assessment.

An additional roll-in cohort of up to 2 patients per primary physician operator at each study site may also be accrued (maximum of 50 roll-in patients total, assuming one primary physician operator per site).

This study does not duplicate any current knowledge existing today on use of the SwitchGuard NPS when used in conjunction with the CGuard Prime™ 80cm in the United States.

02

Conditions studied

  • Carotid Artery Stenosis

Browse trials for

Keywords

  • Transcarotid Artery Revascularization
  • Carotid Endarterectomy
03

In context

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

This study's planned enrollment of 103 is close to the median of 102 across 192 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

InspireMD is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is willing and able to provide appropriate study-specific , follow protocol procedures, and comply with follow-up visit requirements.
  2. Patient is diagnosed with carotid artery disease treatable with a Carotid Artery Stent via a Transcarotid Artery Revascularization approach and is either symptomatic or asymptomatic, defined as:

    Symptomatic carotid stenosis ≥ 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack () or stroke within the last 6 months ipsilateral to the side of the stenosis OR asymptomatic carotid stenosis ≥ 80%

  3. High Risk condition for CEA: at least one, as shown below:

Comorbid conditions:

Age ≥ 70 (maximum 82 years) CCS angina class 3-4 or unstable angina Congestive Heart Failure (CHF) class III-IV (LVEF) ≤ 35% MI ≥ 72 hours and \< 6 weeks pre-procedure Multi-vessel CAD (≥ 2 vessels >70% stenosis) and history of angina (COPD) with \<50 Permanent contralateral cranial nerve injury/paralysis Restenosis from previous carotid endarterectomy (CEA) Planned coronary artery bypass grafting (CABG) or valve replacement surgery between 31-60 days after CAS Abdominal aortic aneurysm surgical repair or Endovascular repair is planned between 31 to 60 days after CAS

Anatomic conditions:

Occlusion of the contralateral CCA or ICA Prior radiation treatment to the neck or a radical neck dissection Severe bilateral ICA stenosis requiring treatment Target lesion at or above the level of the jaw (C2) or below the clavicle Severe tandem lesions Inability to extend the neck due to cervical disorders Laryngeal palsy or laryngectomy Prior head and neck surgery in the region of the carotid artery Tracheostomy or tracheostoma Spinal immobility of the neck

Exclusion criteria

Exclusion Criteria:

  1. Patient had or will have an interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index carotid procedure
  2. Patient had or will have open heart surgery or valvular intervention (percutaneous or surgical), or any major operation, within 30 days before or after the index carotid procedure
  3. Vascular anatomy that would preclude safe sheath insertion or deliverability of stent
  4. Previously placed stent in the ipsilateral ICA or CCA
  5. Total occlusion or presence of a "string sign" of the ipsilateral ICA or CCA
  6. Presence of a filling defect of the target lesion
  7. Tandem lesions, which cannot be covered by a single CGuard Prime stent
  8. Stenosis of the innominate artery or proximal CCA requiring revascularization
  9. Open neck stoma
  10. History of bleeding diatheses or coagulopathy
  11. Hypercoagulable state
  12. Alternative source of cerebral embolus, including but not limited to:

Chronic atrial fibrillation Episode(s) of paroxysmal atrial fibrillation within the past 6 months or history of paroxysmal atrial fibrillation requiring chronic anticoagulation Knowledge of cardiac sources of embolus (e.g. left ventricular aneurysm, intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma) Recently (\<60 days) implanted heart valve (either surgically or endovascularly) as a known source of emboli as confirmed on echocardiogram, Abnormal angiographic findings: ipsilateral intracranial or extracranial arterial stenosis (as determined by angiography or CTA/MRA 6 months prior to index procedure) greater in severity than the lesion to be treated; cerebral aneurysm > 5mm; AVM (arteriovenous malformation) of the cerebral vasculature, or other abnormal angiographic findings Known sensitivity or allergy to nickel or titanium.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (estimated)

Study arms

  • Experimental
    Single Arm

    SwitchGuardTM NPS

    Device: SwitchGuardTM NPS

Interventions

  • DeviceSwitchGuardTM NPS

    The CGuard Prime™ 80 will be used in conjunction with the SwitchGuard™ NPS for the carotid artery stenting implantation procedure that will be performed by physician investigators experienced with transcarotid artery revascularization.

06

What researchers measure

Primary outcomes

  1. Composite primary endpoint

    Incidence of the composite primary endpoint comprised of Death (all-cause mortality), all Stroke, or Myocardial Infarction (DSMI) through 30-days post-index procedure, based on Clinical Events Committee (CEC) adjudication.

    Time frame: 30 days

Secondary outcomes

  1. Rate of all death within 30 days of the procedure

    Time frame: 30 days

  2. Rate of cardiac death within 30 days of the index procedure

    Time frame: 30 days

  3. Rate of neurological death within 30 days of the index procedure

    Time frame: 30 days

  4. Rate of all strokes within 30 days of the procedure

    Time frame: 30 days

  5. Rate of major stroke within 30 days of the procedure

    Time frame: 30 days

  6. Rate of minor stroke within 30 days of the procedure

    Time frame: 30 days

  7. Rate of ipsilateral stroke within 30 days of the procedure

    Time frame: 30 days

  8. Rate of MI within 30 days of the procedure

    Time frame: 30 days

  9. Composite of death or stroke rate within 30 days of the procedure

    Time frame: 30 days

  10. Rate of cranial nerve injury within 30 days of the procedure

    Time frame: 30 days

  11. Access site complications (arterial/venous)

    Time frame: At procedure

  12. All device-related serious adverse events within 30 days of the procedure

    Time frame: 30 days

  13. Acute success for the SwitchGuard NPS

    Successful insertion of the SwitchGuard NPS into the vasculature, followed by flow reversal, and the removal of the SwitchGuard NPS from the vasculature.

    Time frame: At procedure

  14. Acute success for CGuard Prime 80cm Delivery System and Stent

    Successful insertion of the delivery system, successful deployment of the stent, and successful retraction of the delivery system when used in conjunction with the SwitchGuard NPS.

    Time frame: At procedure

  15. Technical Success for the CGuard Prime 80cm Delivery System and Stent

    Technical Success Rate is defined as the number of patients with at least one CGuard Prime™ 80 device successfully delivered and deployed with final residual diameter stenosis \< 30% following final post-balloon dilatation (if performed) divided by the total number of patients where CGuard Prime™ 80 device deployment was attempted when used in conjunction with the SwitchGuard NPS during a TCAR procedure.

    Time frame: At procedure

  16. Procedural success

    Acute device success for CGuard Prime 80cm Delivery System and Stent, AND acute device success for SwitchGuard NPS, AND freedom from the composite of death, all stroke or MI at 30-day post-procedure.

    Time frame: 30 days

  17. Treatment Success for the CGuard Prime 80cm Delivery System and Stent

    Treatment Success Rate is defined as the number of patients who meet CGuard Prime™ 80 Technical Success Rate without experiencing death, stroke or MI through 30-day post-procedure, divided by the total number of patients where CGuard Prime™ 80 device deployment was attempted when used in conjunction with the SwitchGuard NPS during a TCAR procedure.

    Time frame: 30 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Feb 2027, 13 months later.

Of 62 interventional studies with no phase under Carotid Stenosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 11, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2028
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07277296
Lead sponsor
InspireMD
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Dec 11, 2025

Study contacts

InspireMD HCC
Contact
HCC@hartclinicalconsultants.com
(800) 831-7819
Hart Clinical Consultants (HCC)
Contact
HCC@hartclinicalconsultants.com
(800) 831-7819
Patrick J Geraghty, MD
principal investigator · Washington University School of Medicine
Patrick Edward Muck, MD
principal investigator · TriHealth Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion